Factor analysis of a scale to assess state self-monitoring in adolescents during interview: a pilot study.

Self-monitoring is the extent to which individuals regulate self-presentation for the sake of desired public appearances. Snyder developed a Self-Monitoring Scale to measure individual differences on this construct. Since the measure could be insensitive to situational influences, it is uncertain whether the short-term self-monitoring elicited by certain social interactions could be examined. The present study explored the factor structures of a state self-monitoring scale which was adapted from 10 items of the Self-Monitoring Scale. Participants took part in an individual interview with an unfamiliar authority, and then completed the State Self-Monitoring Scale. Two samples of adolescents (N=98 and N=95) were tested. Exploratory factor analysis and confirmatory factor analysis using the two samples indicated that the 9-item State Self-Monitoring Scale had two stable factors. There was a statistically significant difference on State Self-monitoring between adolescents with high and low academic achievement, supporting the validity of the scale.

Apelin-13 attenuates high glucose-induced calcification of MOVAS cells by regulating MAPKs and PI3K/AKT pathways and ROS-mediated signals.

Vascular calcification (VC) is an inducement of many cardiovascular diseases. Clinic evidences have confirmed that diabetes was the independent risk factor for VC, and the mechanism has not been well explored. Apelin as a ligand molecule is widely found in the cardiovascular system and showed potential in inhibiting VC, but the inhibitory effect and mechanism of apelin-13 against high glucose-induced VC have not been investigated yet. Herein, apelin-13 was employed to inhibit high glucose-induced VC in mouse aortic vascular smooth muscle cells (MOVAS), and the underlying mechanism was explored. The results showed that apelin-13 significantly inhibited high glucose-induced cells proliferation, migration and invasion of MOVAS cells. Apelin-13 also effectively attenuated high glucose-induced calcification by inhibiting alkaline phosphatase (ALP) activity and expression. Further investigation revealed that apelin-13 dramatically suppressed high glucose-induced DNA damage through inhibiting reactive oxide species (ROS) generation. Moreover, apelin-13 also effectively improved high glucose-induced dysfunction of MAPKs and PI3K/AKT. Inhibition of ERK by inhibitor (U0126) significantly blocked high glucose-induced calcification, which further confirmed the significance of MAPKs. Taken together, these results suggested that apelin-13 had the potential to attenuate high glucose-induced calcification of MOVAS cells by inhibiting ROS-mediated DNA damage and regulating MAPKs and PI3K/AKT pathways. Our findings validated the strategy of using apelin-13 maybe a novel way in treating high glucose-mediated VC.

Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.

Tumor angiogenesis plays a crucial role in tumor growth, progression and metastasis, and suppression of tumor angiogenesis has been considered as a promising anticancer strategy. Salinomycin (SAL), an antibiotic, displays novel anticancer potential against several human cancer cells in vitro and in vivo. However, little information concerning its anti-angiogenic properties is available. Therefore, the anti­angiogenic effect of SAL and the underlying mechanism in human glioma were evaluated in the present study. The results indicated that SAL treatment significantly inhibited human umbilical vein endothelial cell (HUVEC) proliferation, migration, invasion and capillary-like tube formation. Further investigation on intracellular mechanisms showed that SAL markedly suppressed FAK and AKT phosphorylation, and downregulated vascular endothelial growth factor (VEGF) expression in HUVECs. Pretreatment of cells with a PI3K inhibitor (LY294002) and FAK inhibitor (PF562271) markedly enhanced SAL-induced inhibition of HUVEC proliferation and migration, respectively. Moreover, U251 human glioma xenograft growth was also effectively blocked by SAL treatment in vivo via inhibition of angiogenesis involving FAK and AKT depho-sphorylation. Taken together, our findings validated that SAL inhibits angiogenesis and human glioma growth through suppression of the VEGF-VEGFR2-AKT/FAK signaling axis, indicating the potential application of SAL for the treatment of human glioma.

Peer-comparison overconfidence: Does it measure bias in self-evaluation?

Overconfidence is generally regarded as one of the most robust findings in the psychology of judgment. A precise method for evaluating overconfidence is essential if researchers are to validate these findings. Although peer-comparison questions are a convenient tool for measuring overconfidence, their validity has been questioned. We employed a specific paradigm to verify the validity, and the respondents were asked to predict a verifiable future event in a real-world setting that allowed empirical checking and comparison between the actual result and the prediction. Studies 1 and 2 found that the actual percentile of overconfidence could be accurately predicted using our initial calculation of participants' peer-comparison overconfidence in answering questions about academic performance. Study 3 found a similar effect when using questions related to job hunting. All studies indicated that peer-comparison questions are valid for measuring bias in self-evaluation. Thus, future studies could employ peer-comparison questions to investigate the domain specificity versus the domain generality of overconfidence.

Comparison of serum anti-Mullerian hormone levels following hysterectomy and myomectomy for benign gynaecological conditions.

OBJECTIVE: To compare serum anti-Mullerian hormone (AMH) levels following hysterectomy and myomectomy. STUDY DESIGN: Prospective longitudinal observational study. Serum AMH, follicle stimulating hormone (FSH) and luteinizing hormone (LH) levels were measured pre-operatively (T1) and 2 days (T2) and 3 months (T3) following hysterectomy and myomectomy in 70 women aged 36-45 years. Hysterectomy (laparoscopy-assisted vaginal hysterectomy=10; total abdominal hysterectomy=25) with conservation of both ovaries for benign diseases of the uterus was performed in 35 women, and myomectomy (laparoscopy myomectomy=15; open myomectomy=20) was performed in another 35 women. The follow-up period was 3 months following surgery. The results were analysed using the t-test or one-way analysis of variance by repeated-measures ANOVA. RESULTS: Serum AMH in the hysterectomy group was 1.08±0.77 ng/ml at T1, 0.78±0.58 ng/ml at T2 and 0.81±0.58 ng/ml at T3; the level was significantly lower at T2 and T3 compared with T1. In the myomectomy group, the corresponding values were 1.54±0.95 ng/ml, 1.18±0.77 ng/ml and 1.50±0.58 ng/ml; serum AMH was significantly lower at T2 compared with T1, but the difference between T3 and T1 was not significant. There were no significant differences in serum FSH and LH in either group between these three time points. CONCLUSION: Serum AMH was significantly lower 2 days and 3 months following hysterectomy compared with the pre-operative level. Following myomectomy, serum AMH was significantly lower than the pre-operative level 2 days following the procedure, but was similar to the pre-operative level 3 months after surgery. Therefore, hysterectomy may have a more lasting adverse effect on ovarian reserve than myomectomy. A long-term study of AMH levels is needed.